Literature DB >> 15676142

Significance of mutations in TGFBR2 and BAX in neoplastic progression and patient outcome in sporadic colorectal tumors with high-frequency microsatellite instability.

Antonia M Fernández-Peralta1, Nargisse Nejda, Soledad Oliart, Vicente Medina, Mariano Moreno Azcoita, Juan J González-Aguilera.   

Abstract

The mutator pathway implied in the development of colorectal cancer is characterized by microsatellite instability (MSI), which is determined by alterations of mismatch repair (MMR) genes. Defects in MMR genes affect repetitive DNA tracts interspersed mostly between coding sequences, and therefore it cannot be expected that they play a role during tumor progression. Genes containing repetitive sequences within their coding regions could be targets for MSI tumorigenesis, but this does not necessarily imply a causal role for the affected gene, because most are probably passenger mutations. We analyzed MSI and TGFBR2 and BAX frameshift mutations to further clarify the relationships between inactivation of the two genes and genomic instability in sporadic colorectal cancer (CRC), and to address how mutations in these genes influence the development of tumors and, eventually, patient outcome. One hundred and fifty-five patients with sporadic CRC were classified according to their MSI status. Frameshift mutations in the two genes were recurrent in high-frequency MSI (MSI-H) tumors, but these tended to be more common in poorly differentiated tumors. A high rate of mutations of TGFBR2 was found in tumors at Dukes' B stage, showing a greater extent of vascular invasion. Finally, in MSI-H tumors, mutations of either gene were associated with a significant decrease in survival. Our results contribute to the understanding of how the TGFBR2 and BAX gene mutations contribute to tumor progression in the mutator phenotype pathway for MSI colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15676142     DOI: 10.1016/j.cancergencyto.2004.05.008

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  7 in total

Review 1.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 2.  Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.

Authors:  Antonia M Fernández-Peralta; Lydia Daimiel; Nargisse Nejda; Daniel Iglesias; Vicente Medina Arana; Juan J González-Aguilera
Journal:  Int J Colorectal Dis       Date:  2009-08-11       Impact factor: 2.571

4.  TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.

Authors:  Kaori Shima; Teppei Morikawa; Mai Yamauchi; Aya Kuchiba; Yu Imamura; Xiaoyun Liao; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

5.  Targeting colorectal cancer stem cells with inducible caspase-9.

Authors:  Kristel Kemper; Hans Rodermond; Selçuk Colak; Catarina Grandela; Jan Paul Medema
Journal:  Apoptosis       Date:  2012-05       Impact factor: 4.677

6.  Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation.

Authors:  Masashi Miguchi; Takao Hinoi; Manabu Shimomura; Tomohiro Adachi; Yasufumi Saito; Hiroaki Niitsu; Masatoshi Kochi; Haruki Sada; Yusuke Sotomaru; Tsuneo Ikenoue; Kunitoshi Shigeyasu; Kohji Tanakaya; Yasuhiko Kitadai; Kazuhiro Sentani; Naohide Oue; Wataru Yasui; Hideki Ohdan
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

Review 7.  Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.

Authors:  Alex Françoso; Patricia Ucelli Simioni
Journal:  Drug Des Devel Ther       Date:  2017-01-11       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.